Arthroscopy 41, 199206 (2025).
The observed changes in plasma alanine and glucagon concentrations with survodutide but not placebo or semaglutide indicate target engagement at both the GCGR and the GLP-1R, highlighting that survodutide is a GCGR/GLP-1R dual agonist and its effects are exerted at both receptors
I lost 30 lbs in 4.5 months
The objective of the STEP 1 study was to compare the effect of a semaglutide SC 2.4 mg injection once weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with overweight or obesity on body weight (primary objective), and cardiovascular risk factors, clinical outcome assessment, glucose metabolism, and other factors related to body weight (secondary objectives)
That compounding caution is well-founded
Whether youre looking for GLP-1 injections, personalized dietary advice, or other health services, were here to help